<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33472">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01923519</url>
  </required_header>
  <id_info>
    <org_study_id>13-PP-06</org_study_id>
    <nct_id>NCT01923519</nct_id>
  </id_info>
  <brief_title>Study of Genic Expression Profiles of the Epithelium of the Nose and Bronchi in Healthy and Allergic Subjects</brief_title>
  <acronym>GENEBRO</acronym>
  <official_title>Study of Genic Expression Profiles of the Epithelium of the Nose and Bronchi in Healthy and Allergic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The respiratory epithelium plays a leading role in the development of allergic respiratory
      disease with barrier function alteration, its repair mechanisms, of anti-viral fight and the
      ability to induce by itself Th2 responses. The majority of allergic asthmatic patients have
      reached concomitant ENT: the concept of &quot;one airway, one disease.&quot; Access to this material
      of epithelial study in the different phenotypes of the disease appears to be crucial. Nasal
      and bronchial epithelial tissues reveal essential differences in particular related to their
      environment (remodeling less intense and a lower sensitivity to the virus in the nose), but
      they nevertheless share many common cellular characteristics.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>genic expression profile of the epithelium</measure>
    <time_frame>3 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>allergic rhinitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>allergic rhinitis and asthma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>witnesses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bronchofiberscopy</intervention_name>
    <arm_group_label>allergic rhinitis</arm_group_label>
    <arm_group_label>allergic rhinitis and asthma</arm_group_label>
    <arm_group_label>witnesses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 18 years and &lt;30 years

          -  isolated allergic rhinitis according to clinical criteria ARIA

          -  absence of asthma whose diagnosis is made based on clinical criteria or mild to
             moderate persistent asthma controlled with a diagnosis is made based on clinical
             criteria

        Exclusion Criteria:

          -  recent rhino-bronchial infection (&lt;6 weeks)

          -  asthma exacerbation in the previous 6 weeks

          -  Chronic disease may in the opinion of the investigators interfere with the results of
             the study or expose them to additional risk.

          -  Treatment with nasal corticosteroids, inhaled or systemic in the past 6 weeks

          -  Current smoking no history of smoking or not smoking for at least 12 months and
             weaned smoking history &lt;5 pack-years)

          -  Special Needs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles MARQUETTE, Pr</last_name>
    <phone>+33 (0)4 92 03 88 83</phone>
    <email>marquette.c@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles MARQUETTE, Pr</last_name>
      <phone>+33(0)4 92 03 88 83</phone>
      <email>marquette.c@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Charles MARQUETTE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>August 13, 2013</lastchanged_date>
  <firstreceived_date>August 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
